Sam Brusco, Associate Editor04.18.24
AtriCure has launched its new cryoSPHERE+ cryoablation probe, which features new insulation technology to lower freeze times by 25% versus the company’s legacy cryosphere device.
cryoSPHERE+ earned U.S. Food and Drug Administration (FDA) 510(k) clearance to temporarily block pain by ablating peripheral nerves in adults, and by ablating intercostal nerves under direct visualization in adolescents (12-21 years of age). The device’s new tech minimizes thermal loss by focusing energy at the ball tip, which the company said offers a faster time to therapeutic temperature.
“cryoSPHERE+ is a meaningful innovation that I believe will improve patient care, enhance outcomes, and enable physicians to perform procedures with greater ease and confidence,” said AtriCure president and CEO Michael Carrel. “Since the launch of our pain management franchise over five years ago, we’ve seen a significant impact on patient’s lives, and with this launch, we look forward to serving even more people in the future.”
AtriCure’s cryoICE platform technology uses a freezing method to block nerves from sending pain signals for several months. The company touts that physicians are adopting Cryo Nerve Block therapy using cryoSPHERE as part of their multimodal pain management strategy because of its long-lasting nature.
cryoSPHERE+ is built on the legacy of the cryoSPHERE device, which was cleared in November 2018 and has been used in more than 60,000 procedures to date.
cryoSPHERE+ earned U.S. Food and Drug Administration (FDA) 510(k) clearance to temporarily block pain by ablating peripheral nerves in adults, and by ablating intercostal nerves under direct visualization in adolescents (12-21 years of age). The device’s new tech minimizes thermal loss by focusing energy at the ball tip, which the company said offers a faster time to therapeutic temperature.
“cryoSPHERE+ is a meaningful innovation that I believe will improve patient care, enhance outcomes, and enable physicians to perform procedures with greater ease and confidence,” said AtriCure president and CEO Michael Carrel. “Since the launch of our pain management franchise over five years ago, we’ve seen a significant impact on patient’s lives, and with this launch, we look forward to serving even more people in the future.”
AtriCure’s cryoICE platform technology uses a freezing method to block nerves from sending pain signals for several months. The company touts that physicians are adopting Cryo Nerve Block therapy using cryoSPHERE as part of their multimodal pain management strategy because of its long-lasting nature.
cryoSPHERE+ is built on the legacy of the cryoSPHERE device, which was cleared in November 2018 and has been used in more than 60,000 procedures to date.